Treatment with vepugratinib (LY3866288) monotherapy yielded responses and displayed tolerability in patients with metastatic urothelial carcinoma harboring FGFR3 alterations, according to data from the dose-optimization portion of the phase 1…
Vepugratinib-Based Therapy Displays Potential in Metastatic FGFR3+ Urothelial Cancer
